Immix Biopharma Inc (IMMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $657.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immix Biopharma Inc (IMMX) Competitors
The companies most similar to Immix Biopharma are Immatics NV (IMTX), Inhibrx Biosciences (INBX) and CorMedix (CRMD). By market cap, Immix Biopharma ranks 7th of the 13 companies on this page; Inhibrx Biosciences (INBX) is the largest at $1.23B.
Peer Comparison
IMMX's ROIC of -14.9% is above the peer median of -53.8%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Immix Biopharma (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Immatics NV (IMTX) | $972.99M | N/A | 17.7x | 0.0% | N/A | 33.5% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Puma Biotechnology Inc (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| MoonLake Immunotherapeutics (MLTX) | $1.06B | N/A | N/A | 0.0% | -54.6% | 0.0% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Climb Bio Inc (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Entera Bio Ltd (ENTX) | $541.57M | N/A | N/A | 0.0% | -8.5% | -100.0% | 0.00% |
| Peer median | $635.41M | 10.7x | 17.7x | 0.0% | -53.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Immix Biopharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immatics NV (IMTX) | Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies... | IMTX competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Puma Biotechnology Inc (PBYI) | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States... | PBYI competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| MoonLake Immunotherapeutics (MLTX) | MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug... | MLTX competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Climb Bio Inc (CLYM) | Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. | CLYM competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Entera Bio Ltd (ENTX) | Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies... | ENTX competitors |
Frequently Asked Questions About IMMX
Who are Immix Biopharma's main competitors?
The companies most similar to Immix Biopharma include Immatics NV (IMTX), Inhibrx Biosciences (INBX), CorMedix (CRMD), Olema Pharmaceuticals (OLMA) and Puma Biotechnology (PBYI), listed from the closest match.
Who is Immix Biopharma's biggest competitor?
Inhibrx Biosciences (INBX) is the largest of the similar companies at $1.23B; Immatics NV (IMTX) is the closest match by business profile, size, sector and industry.
How does IMMX stock compare with its competitors?
IMMX's net margin is 0.0% against a peer median of 0.0%.
Which of Immix Biopharma's competitors pays a higher dividend?
Immix Biopharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Immix Biopharma bigger than its competitors?
No. Immix Biopharma is 7th by market cap among the 13 companies on this page; the largest is Inhibrx Biosciences (INBX) at $1.23B.
IMMX pages: Overview, Earnings, Forecast, Financials, Competitors